Tonix Pharmaceuticals (TNXP) to Present at World Vaccine Congress

3 days ago

Tonix Pharmaceuticals set to present at the World Vaccine Congress Washington 2025.
Analysts predict a significant potential upside for TNXP based on current price targets.
Brokerage firms rate the stock as "Outperform," indicating positive expectations.

Tonix Pharmaceuticals Holding Corp. (TNXP) is poised to make a significant impact at the upcoming World Vaccine Congress Washington 2025, scheduled for April 22-24. The company plans to deliver an oral presentation and facilitate a thought-provoking panel discussion. Highlighting its robust pipeline, Tonix will discuss TNX-102 SL for fibromyalgia, for which an FDA decision is anticipated by August. This underscores the company's commitment to advancing its CNS and immunology-focused innovations.

Wall Street Analysts' Forecast

Wall Street remains optimistic about Tonix Pharmaceuticals' potential growth. According to data sourced from three analysts, the average one-year price target for TNXP is $406.67. This projection spans from a conservative low estimate of $50.00 to an ambitious high of $1,100.00, suggesting a remarkable upside potential of 2,245.94% from the current price of $17.33. For those seeking more detailed insights, further information is available on the Tonix Pharmaceuticals Holding Corp (TNXP, Financial) Forecast page.

Brokerage Firms' Ratings

Tonix Pharmaceuticals is currently evaluated by 1 brokerage firm that provides a consensus recommendation with an average rating of 2.0, categorizing the stock as "Outperform." In the rating spectrum, 1 stands for a Strong Buy, while 5 indicates a Sell. This favorable recommendation highlights the promising outlook professionals have for TNXP's future performance.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.